Center for Observational and Real-World Evidence, MSD, Madrid, Spain.
Center for Observational and Real-World Evidence, MSD, Vilnius, Lithuania.
J Med Econ. 2024 Apr;27(sup2):30-40. doi: 10.1080/13696998.2024.2374684. Epub 2024 Jul 15.
The economic and mortality burden of cancer is high worldwide. In Europe, cancer was responsible for 1.3 million deaths in 2020 and incurred an estimated cost of €50 billion from premature mortality. Human papillomavirus (HPV) and hepatitis B virus (HBV) are among the leading causes of infection-related cancers despite the availability of effective vaccines against these infections. This analysis estimated the mortality and productivity loss of HBV- and HPV-associated cancers that could be preventable through vaccination across European regions.
Institute for Health Metrics Evaluation (IHME) data were used to estimate mortality, years of life lost (YLL), and the value of years of life lost (VYLL) from five HBV- and HPV-related cancers (oral cavity, oropharynx, larynx, cervical, and liver cancers) across 40 European countries in 2019. Preventable deaths and YLL were estimated based on fractions attributable to infections. Data from the World Bank on GDP per capita were used to estimate the VYLL. The robustness of these results was explored with sensitivity and scenario analyses.
In 2019, 31,906 cancer deaths resulted in an economic burden of €18,521,614,725 due to productivity losses across Europe. HPV-related cervical cancer had the highest mortality (19,473 deaths) and economic burden (€10,706,253,185). HBV-related liver cancer and HPV-related larynx, oral cavity, and oropharynx cancers also had a substantial burden, particularly in males. Eastern Europe had the highest YLL (308,179; 39%) and Western Europe was responsible for the greatest VYLL (€8,281,306,504; 45%), although the highest VYLL per death was in Northern Europe (€923,638). HPV-related oropharynx cancer had the highest VYLL per death (€656,607).
HPV- and HBV-related cancer deaths are associated with substantial mortality and productivity losses in Europe, which could be reduced by the continued prioritization and implementation of prophylactic public health measures including systematic awareness, vaccination, and screening efforts.
癌症在全球范围内造成了巨大的经济和死亡负担。在欧洲,2020 年癌症导致 130 万人死亡,并因过早死亡造成了约 500 亿欧元的估计成本。尽管存在针对这些感染的有效疫苗,但人乳头瘤病毒(HPV)和乙型肝炎病毒(HBV)仍是导致感染相关癌症的主要原因之一。本分析估计了在整个欧洲地区通过疫苗接种可以预防的与 HBV 和 HPV 相关的癌症的死亡率和生产力损失。
使用健康计量评估研究所(IHME)的数据,估算了 2019 年在欧洲 40 个国家中与 5 种 HBV 和 HPV 相关癌症(口腔、口咽、喉、宫颈和肝癌)相关的死亡率、寿命损失年(YLL)和寿命损失价值(VYLL)。根据归因于感染的部分,估算了可预防的死亡人数和 YLL。使用世界银行的人均 GDP 数据来估算 VYLL。通过敏感性和情景分析探讨了这些结果的稳健性。
2019 年,欧洲共有 31906 例癌症死亡,导致生产力损失造成 18521614725 欧元的经济负担。与 HPV 相关的宫颈癌死亡率最高(19473 例死亡),经济负担最重(10706253185 欧元)。HBV 相关的肝癌和 HPV 相关的喉癌、口腔癌和口咽癌也造成了相当大的负担,特别是在男性中。东欧的 YLL 最高(308179 年;39%),西欧的 VYLL 最高(8281306504 欧元;45%),尽管每例死亡的 VYLL 最高的是北欧(923638 欧元)。与 HPV 相关的口咽癌每例死亡的 VYLL 最高(656607 欧元)。
在欧洲,与 HPV 和 HBV 相关的癌症死亡与巨大的死亡率和生产力损失有关,如果继续优先考虑和实施包括系统意识、疫苗接种和筛查工作在内的预防性公共卫生措施,可以减少这些死亡和损失。